Literature DB >> 1138925

Interaction of myasthenic serum globulin with the acetylcholine receptor.

R R Almon, S H Appel.   

Abstract

A serum factor from patients with myasthenia gravis which inhibited the binding of 125I-labeled alpha-bungarotoxin to acetylcholine receptor extracted with Triton X-100 from rat muscle has been studied in detail. The inhibitory activity was localized to the IgG fraction based upon the fractionations by sodium sulfate precipitation and DEAE chromatography as well as reaction with anti-IgG globulin. The myasthenic globulin inhibited toxin binding to receptors extracted from degenerated muscle but did not inhibit toxin binding to normal junctional receptors. At saturation levels of myasthenic globulin, the number of denervated acetylcholine receptors available for toxin binding was reduced approx. 50 percent. The myastehnic globulin was found to bind to denervated acetylcholine receptors but not to normal acetylcholine receptors by a radioimmunoassay technique in which myasthenic globulin incubated with 125I-labeled alpha bungarotoxin-receptor complexes was precipitated by anti-IgG serum. The globulin binding was saturable over the same range as inhibition of toxin binding. The data suggest that the myasthenic IgC binds to a site on the receptor complex juxtaposed to the acetylcholine receptor site. The myasthenic globulin appears to be a useful probe for investigation differences between acetylcholine receptors extracted from normal and denervated muscle and for investigating the pathogenesis of myasthenia gravis.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1138925     DOI: 10.1016/0005-2795(75)90217-2

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  17 in total

1.  Steroids induce acetylcholine receptors on cultured human muscle: implications for myasthenia gravis.

Authors:  I Kaplan; B T Blakely; G K Pavlath; M Travis; H M Blau
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

2.  Accessibility to antibodies of acetylcholine receptors in the neuromuscular junction.

Authors:  A D Zurn; B W Fulpius
Journal:  Clin Exp Immunol       Date:  1976-04       Impact factor: 4.330

Review 3.  Tissue-specific antibodies in myasthenia gravis.

Authors:  A Vincent
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1979

4.  [A transferable "Myasthenogenic" factor in the serum of patients with myasthenia gravis.].

Authors:  K V Toyka; D B Drachman; A Pestronk; K H Fischbeck; I Kao
Journal:  J Neurol       Date:  1976-06       Impact factor: 4.849

5.  Effect of sera from seronegative myasthenia gravis patients on neuromuscular junctions.

Authors:  Rumi Sato; Shiho Imamoto; Iku Utsnomiya; Terumasa Chiba; Kyoji Taguchi; Kenji Abe; Keiko Tanaka; Tadashi Miyatake
Journal:  Neurol Sci       Date:  2013-02-07       Impact factor: 3.307

6.  Differences in the interaction of acetylcholine receptor antibodies with receptor from normal, denervated and myasthenic human muscle.

Authors:  A K Lefvert
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-01       Impact factor: 10.154

7.  Anti-acetylcholine receptor antibodies.

Authors:  A Vincent; J Newsom Davis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-07       Impact factor: 10.154

8.  Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays.

Authors:  A Vincent; J Newsom-Davis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-12       Impact factor: 10.154

9.  Myasthenia gravis. Anti-acetylcholine receptor antibodies.

Authors:  D Cerrato; C Ariano; L La Mantia; F Fiacchino; A Sghirlanzoni; A Nespolo; F Corridori; F Cornelio
Journal:  Ital J Neurol Sci       Date:  1981-05

10.  Antibodies from patients with myasthenia gravis recognize determinants unique to extrajunctional acetylcholine receptors.

Authors:  C B Weinberg; Z W Hall
Journal:  Proc Natl Acad Sci U S A       Date:  1979-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.